Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $71.0 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $71.0 million, up 1.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $281.6 million (down 6.37% YoY), and the FY2025 annual result was $76.8 million, up 1.64% from the prior year.
• Liabilities and Shareholders Equity came in at $71.0 million for Q1 2026 at Cumberland Pharmaceuticals, down from $76.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $96.7 million in Q1 2022 to a low of $65.9 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $81.5 million (2024), against an average of $81.5 million.
• Across the five-year window, Liabilities and Shareholders Equity advanced 10.02% in 2022 and dropped 14.2% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Liabilities and Shareholders Equity stood at $92.9 million in 2022, then declined by 12.0% to $81.8 million in 2023, then slipped by 7.57% to $75.6 million in 2024, then grew by 1.64% to $76.8 million in 2025, then retreated by 7.59% to $71.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $71.0 million (Q1 2026), $76.8 million (Q4 2025), and $65.9 million (Q3 2025), per Business Quant data.